BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 32542788)

  • 1. Nonpeghylated liposomal doxorubicin combination regimen (R-COMP) for the treatment of lymphoma patients with advanced age or cardiac comorbidity.
    Rigacci L; Annibali O; Kovalchuk S; Bonifacio E; Pregnolato F; Angrilli F; Vitolo U; Pozzi S; Broggi S; Luminari S; Merli F; Spina M; Bolis S; Margiotta-Casaluci G; Scalzulli R; Cox C; Mamusa AM; Santoro A; Zinzani PL; Ferrari S; Gini G; Vigliotti ML; Mulè A; Flenghi L;
    Hematol Oncol; 2020 Oct; 38(4):478-486. PubMed ID: 32542788
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nonpegylated Liposomal Doxorubicin as a Component of R-CHOP Is an Effective and Safe Alternative to Conventional Doxorubicin in the Treatment of Patients With Diffuse Large B-Cell Lymphoma and Preexisting Cardiac Diseases.
    Rohlfing S; Aurich M; Schöning T; Ho AD; Witzens-Harig M
    Clin Lymphoma Myeloma Leuk; 2015 Aug; 15(8):458-63. PubMed ID: 25899891
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiotoxicity with rituximab, cyclophosphamide, non-pegylated liposomal doxorubicin, vincristine and prednisolone compared to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone in frontline treatment of patients with diffuse large B-cell lymphoma: A randomised phase-III study from the Austrian Cancer Drug Therapy Working Group [Arbeitsgemeinschaft Medikamentöse Tumortherapie AGMT](NHL-14).
    Fridrik MA; Jaeger U; Petzer A; Willenbacher W; Keil F; Lang A; Andel J; Burgstaller S; Krieger O; Oberaigner W; Sihorsch K; Greil R
    Eur J Cancer; 2016 May; 58():112-21. PubMed ID: 26990931
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biweekly rituximab, cyclophosphamide, vincristine, non-pegylated liposome-encapsulated doxorubicin and prednisone (R-COMP-14) in elderly patients with poor-risk diffuse large B-cell lymphoma and moderate to high 'life threat' impact cardiopathy.
    Corazzelli G; Frigeri F; Arcamone M; Lucania A; Rosariavilla M; Morelli E; Amore A; Capobianco G; Caronna A; Becchimanzi C; Volzone F; Marcacci G; Russo F; De Filippi R; Mastrullo L; Pinto A
    Br J Haematol; 2011 Sep; 154(5):579-89. PubMed ID: 21707585
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonpegylated liposomal doxorubicin combination regimen in patients with diffuse large B-cell lymphoma and cardiac comorbidity. Results of the HEART01 phase II trial conducted by the Fondazione Italiana Linfomi.
    Luminari S; Viel E; Ferreri AJM; Zaja F; Chimienti E; Musuraca G; Tucci A; Balzarotti M; Tani M; Salvi F; Pesce EA; Ferrari A; Liberati AM; Spadea A; Marino D; Bruno-Ventre M; Volpetti S; Bottelli C; Ravaioli E; Merli F; Spina M
    Hematol Oncol; 2018 Feb; 36(1):68-75. PubMed ID: 28524259
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pegylated liposomal doxorubicin replacing conventional doxorubicin in standard R-CHOP chemotherapy for elderly patients with diffuse large B-cell lymphoma: an open label, single arm, phase II trial.
    Oki Y; Ewer MS; Lenihan DJ; Fisch MJ; Hagemeister FB; Fanale M; Romaguera J; Pro B; Fowler N; Younes A; Astrow AB; Huang X; Kwak LW; Samaniego F; McLaughlin P; Neelapu SS; Wang M; Fayad LE; Durand JB; Rodriguez MA
    Clin Lymphoma Myeloma Leuk; 2015 Mar; 15(3):152-8. PubMed ID: 25445468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Non-pegylated liposomal doxorubicin in combination with cyclophosphamide, vincristine, prednisone and rituximab for the treatment of non-Hodgkin's lymphoma: study of 26 patients].
    Moreno M; Sancho JM; Gardella S; Coll R; García O; Gallardo D; Ribera JM
    Med Clin (Barc); 2010 Jan; 134(2):72-5. PubMed ID: 19913261
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modern Management of Anthracycline-Induced Cardiotoxicity in Lymphoma Patients: Low Occurrence of Cardiotoxicity with Comprehensive Assessment and Tailored Substitution by Nonpegylated Liposomal Doxorubicin.
    Olivieri J; Perna GP; Bocci C; Montevecchi C; Olivieri A; Leoni P; Gini G
    Oncologist; 2017 Apr; 22(4):422-431. PubMed ID: 28275118
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liposomal doxorubicin supercharge-containing front-line treatment in patients with advanced-stage diffuse large B-cell lymphoma or classical Hodgkin lymphoma: Preliminary results of a single-centre phase II study.
    Picardi M; Giordano C; Pugliese N; Esposito M; Fatigati M; Muriano F; Rascato MG; Della Pepa R; D'Ambrosio A; Vigliar E; Troncone G; Russo D; Mascolo M; Esposito G; Prastaro M; Esposito R; Tocchetti CG; Fonti R; Mainolfi C; Del Vecchio S; Pane F
    Br J Haematol; 2022 Sep; 198(5):847-860. PubMed ID: 35819919
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonpegylated liposomal doxorubicin (MyocetTM) combination (R-COMP) chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL): results from the phase II EUR018 trial.
    Luminari S; Montanini A; Caballero D; Bologna S; Notter M; Dyer MJS; Chiappella A; Briones J; Petrini M; Barbato A; Kayitalire L; Federico M
    Ann Oncol; 2010 Jul; 21(7):1492-1499. PubMed ID: 20007997
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liposome-encapsulated doxorubicin in combination with cyclophosphamide, vincristine, prednisone and rituximab in patients with lymphoma and concurrent cardiac diseases or pre-treated with anthracyclines.
    Rigacci L; Mappa S; Nassi L; Alterini R; Carrai V; Bernardi F; Bosi A
    Hematol Oncol; 2007 Dec; 25(4):198-203. PubMed ID: 17654614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. R-COMP versus R-CHOP as first-line therapy for diffuse large B-cell lymphoma in patients ≥60 years: Results of a randomized phase 2 study from the Spanish GELTAMO group.
    Sancho JM; Fernández-Alvarez R; Gual-Capllonch F; González-García E; Grande C; Gutiérrez N; Peñarrubia MJ; Batlle-López A; González-Barca E; Guinea JM; Gimeno E; Peñalver FJ; Fuertes M; Bastos M; Hernández-Rivas JÁ; Moraleda JM; García O; Sorigué M; Martin A
    Cancer Med; 2021 Feb; 10(4):1314-1326. PubMed ID: 33492774
    [TBL] [Abstract][Full Text] [Related]  

  • 13. R-CHOP versus R-COMP: are they really equally effective?
    Mian M; Wasle I; Gamerith G; Mondello P; Melchardt T; Jäger T; Linkesch W; Fiegl M
    Clin Oncol (R Coll Radiol); 2014 Oct; 26(10):648-52. PubMed ID: 24929649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Direct-Acting Antivirals in Hepatitis C Virus-Associated Diffuse Large B-cell Lymphomas.
    Merli M; Frigeni M; Alric L; Visco C; Besson C; Mannelli L; Di Rocco A; Ferrari A; Farina L; Pirisi M; Piazza F; Loustaud-Ratti V; Arcari A; Marino D; Sica A; Goldaniga M; Rusconi C; Gentile M; Cencini E; Benanti F; Rumi MG; Ferretti VV; Grossi P; Gotti M; Sciarra R; Tisi MC; Cano I; Zuccaro V; Passamonti F; Arcaini L
    Oncologist; 2019 Aug; 24(8):e720-e729. PubMed ID: 30552159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence of interstitial pneumonitis in non-Hodgkin's lymphoma patients receiving immunochemotherapy with pegylated liposomal doxorubicin and rituximab.
    Zhou T; Shen Q; Peng H; Chao T; Zhang L; Huang L; Yang K; Thapa S; Yu S; Jiang Y
    Ann Hematol; 2018 Jan; 97(1):141-147. PubMed ID: 29086009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical prognostic factors of diffuse large B cell non-Hodgkin lymphoma: a retrospective study.
    Abdelhamid T; Samra M; Ramadan H; Mehessin M; Mokhtar N
    J Egypt Natl Canc Inst; 2011 Mar; 23(1):17-24. PubMed ID: 22099932
    [TBL] [Abstract][Full Text] [Related]  

  • 17. R-COMP 21 for frail elderly patients with aggressive B-cell non-Hodgkin lymphoma: a pilot study.
    Visani G; Ferrara F; Alesiani F; Ronconi S; Catarini M; D'adamo F; Guiducci B; Bernardi D; Barulli S; Piccaluga P; Rocchi M; Isidori A
    Leuk Lymphoma; 2008 Jun; 49(6):1081-6. PubMed ID: 18569635
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rituximab as consolidation therapy did not improve outcome in patients with diffuse large B-cell lymphoma at complete response after dose-dense chemotherapy (CHOP-14).
    Avilès A; Nambo MJ; Huerta-Guzmàn J; Silva L; Neri N
    Cancer Biother Radiopharm; 2015 Apr; 30(3):107-10. PubMed ID: 25871407
    [TBL] [Abstract][Full Text] [Related]  

  • 19. De novo treatment of diffuse large B-cell lymphoma with rituximab, cyclophosphamide, vincristine, gemcitabine, and prednisolone in patients with cardiac comorbidity: a United Kingdom National Cancer Research Institute trial.
    Fields PA; Townsend W; Webb A; Counsell N; Pocock C; Smith P; Jack A; El-Mehidi N; Johnson PW; Radford J; Linch DC; Cunnningham D
    J Clin Oncol; 2014 Feb; 32(4):282-7. PubMed ID: 24220559
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CHOP-rituximab with pegylated liposomal doxorubicin for the treatment of elderly patients with diffuse large B-cell lymphoma.
    Zaja F; Tomadini V; Zaccaria A; Lenoci M; Battista M; Molinari AL; Fabbri A; Battista R; Cabras MG; Gallamini A; Fanin R
    Leuk Lymphoma; 2006 Oct; 47(10):2174-80. PubMed ID: 17071492
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.